Ultragenyx Pharmaceutical (RARE) Q3 2024 Earnings
RARE·Reported November 5, 2024·After market close
Ultragenyx Pharmaceutical reported Q3 2024 revenue of $139.5M, missed analyst consensus of $146.5M by $7.0M. Diluted EPS came in at $-1.40, beat the $-1.45 consensus by $0.05.
Revenue
$139.5Mmissed by $7.0M
Consensus: $146.5MDiluted EPS
$-1.40beat by $0.05
Consensus: $-1.45
Financial Snapshot
Trailing eight quarters through Q3 2024
Q3 2024 Earnings FAQ
Common questions about Ultragenyx Pharmaceutical's Q3 2024 earnings report.
Ultragenyx Pharmaceutical (RARE) reported Q3 2024 earnings on November 5, 2024 after market close.
Ultragenyx Pharmaceutical reported revenue of $139.5M and diluted EPS of $-1.40 for Q3 2024.
Revenue missed the consensus estimate of $146.5M by $7.0M. EPS beat the consensus estimate of $-1.45 by $0.05.
You can read the 10-Q periodic report (0000950170-24-121679) directly on SEC EDGAR. The filing index links above go to sec.gov.